Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.

Hurwitz MD, Halabi S, Ou SS, McGinnis LS, Keuttel MR, Dibiase SJ, Small EJ.

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):814-9. doi: 10.1016/j.ijrobp.2008.01.010. Epub 2008 Apr 11.

PMID:
18407435
2.

Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.

D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW.

JAMA. 2008 Jan 23;299(3):289-95. doi: 10.1001/jama.299.3.289.

PMID:
18212313
4.

Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019.

Lee WR, Bae K, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H.

Cancer. 2007 Apr 15;109(8):1506-12.

5.

15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience.

Sylvester JE, Grimm PD, Blasko JC, Millar J, Orio PF 3rd, Skoglund S, Galbreath RW, Merrick G.

Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):57-64. Epub 2006 Nov 2.

PMID:
17084544
6.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H.

Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74.

PMID:
16798415
7.

Late gastrointestinal toxicity after radiation for prostate cancer.

Giordano SH, Lee A, Kuo YF, Freeman J, Goodwin JS.

Cancer. 2006 Jul 15;107(2):423-32.

8.

A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019.

Lee WR, DeSilvio M, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H.

Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):804-9. Epub 2005 Nov 14.

PMID:
16289906
9.

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G, Kovacev O, D'Este C; Trans-Tasman Radiation Oncology Group..

Lancet Oncol. 2005 Nov;6(11):841-50.

PMID:
16257791
10.

Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):32-43.

PMID:
15629591
11.

Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis.

Singh AM, Gagnon G, Collins B, Niroomand-Rad A, McRae D, Zhang Y, Regan J, Lynch J, Dritschilo A.

Prostate. 2005 Jan 1;62(1):54-60.

PMID:
15389809
12.
13.

Combined modality treatment in the management of high-risk prostate cancer.

Stock RG, Cahlon O, Cesaretti JA, Kollmeier MA, Stone NN.

Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1352-9.

PMID:
15275720
14.

Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.

Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.

Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):929-43.

PMID:
14575823
15.

Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications.

Stock RG, Stone NN, Cesaretti JA.

Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):448-53.

PMID:
12738319
16.

Simultaneous irradiation for prostate cancer: intermediate results with modern techniques.

Critz FA, Williams WH, Levinson AK, Benton JB, Holladay CT, Schnell FJ Jr.

J Urol. 2000 Sep;164(3 Pt 1):738-41; discussion 741-3.

PMID:
10953137
17.

Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.

Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE.

Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1261-6.

PMID:
10889379
18.

Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer.

Cavanagh W, Blasko JC, Grimm PD, Sylvester JE.

Semin Urol Oncol. 2000 May;18(2):160-5.

PMID:
10875459
19.

Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer.

Critz FA, Williams WH, Benton JB, Levinson AK, Holladay CT, Holladay DA.

J Urol. 2000 Apr;163(4):1085-9.

PMID:
10737471
20.

Complications after prostate brachytherapy in the Medicare population.

Benoit RM, Naslund MJ, Cohen JK.

Urology. 2000 Jan;55(1):91-6.

PMID:
10654901

Supplemental Content

Support Center